FDA advisory committee votes in favor of XELJANZ® (tofacitinib citrate) for the treatment of active psoriatic arthritis

4th August 2017 Uncategorised 0

Pfizer

More: FDA advisory committee votes in favor of XELJANZ® (tofacitinib citrate) for the treatment of active psoriatic arthritis
Source: MDlinx